Despite the constant improvement of therapeutical options, heart failure (HF) remains
associated with high mortality and morbidity. While new developments in guideline …

Renin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the
pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last …

Aims ACTIVITY‐HF was a randomized, double‐blind, active‐controlled study, which
assessed the short‐term effect of sacubitril/valsartan compared with the active comparator …

Increased ventilation relative to metabolic demands, indicating alveolar hyperventilation
and/or increased physiological dead space (excess ventilation), is a key cause of exertional …

Purpose Sacubitril/valsartan is a mainstay of the treatment of heart failure with reduced
ejection fraction (HFrEF); however, its effects on exercise performance yielded conflicting …

Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced
ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity …

Several guidelines have recommended the use of angiotensin receptor neprilysin inhibitors
(ARNIs) as replacement for angiotensin-converting enzyme inhibitors in the management of …

Aim Sacubitril/valsartan treatment reduces mortality and hospitalizations in heart failure with
reduced ejection fraction but has limited application in hypertrophic cardiomyopathy (HCM) …

Background: In elderly chronic heart failure (HF) patients, activities of daily living (ADLs)
require the use of a high proportion of patients' peak aerobic capacity, heart rate, and …

We performed a meta-analysis investigating the efficacy and adverse effects of sacubitril–
valsartan in various types of heart failure including more recent studies and a larger sample …